Formulation and in-vitroevaluation of gastro retaintive bi-layered floating tablet of sucralfate and metoprolol succinate

Formulation and evaluation and selection of best formulation of 500 mg Bi-Layer Floating Tablet having 214 mg Ulcer protective Sucralfate as Immediate Release Layer and 286mg of antihypertensive Metoprolol Succinate as Floating Sustained Release layer.Best formulations are selected from 15 formulations of Sucralfate and 10 formulations of Metoprolol Succinate according to pre formulation study , in vitro evaluation, accelerated stability study. Then Bi Layered Floating Tablet is compressed and In vitro evaluation is done. In presence of major amount of Crospovidone, Lactose MFL,MCC PH 101,Sodium Bicarbonate, HPC-L the immediate release formulation of Sucralfate (SF10) produce DT 6.29± 0.047 min ,Drug content 99.95% in presence of acid medium of stomach. In presence of majore amount of HPMC K 100,Sodium Bicarbonate ,Aerosil, Udragit the cotrolled release layer (MSF6) produce drug release 102.11% in upper intestine This formulation(SF10 + MSF6) generate maximum prolonged gastro retention and satisfy GRDDS in patients having Stomach Ulcer with Hypertension in pregnancy and lactation.